Valuation: Pluristem Therapeutics

Market Cap 22.55M 19.59M 18.19M 16.77M 31.6M 2.15B 32.17M 215M 84.31M 1.07B 84.68M 82.83M 3.6B P/E 2024
-1.45x
P/E 2025 -1.39x
Enterprise Value 35.99M 31.26M 29.03M 26.77M 50.43M 3.44B 51.34M 344M 135M 1.71B 135M 132M 5.74B EV / Sales 2024
93.2x
EV / Sales 2025 39.1x
Free-Float
53.43%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 54 28/03/2017
Director of Finance/CFO 42 30/11/2022
Chief Operating Officer - 31/12/2024
Director TitleAgeSince
Director/Board Member 54 31/01/2015
Director/Board Member 56 05/01/2021
Director/Board Member 64 31/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
+3.38%-1.33% - - 16.83M
+0.72%+4.71%+0.31%+13.58% 49.37B
-3.95%+14.70%+24.15%+5.15% 39.14B
+6.22%+1.81%+419.17%+647.45% 40.85B
-1.57%-1.44%+7.38%+43.06% 35.81B
+5.56%+11.70%+11.64%+51.50% 30.5B
-0.39%-0.63% - - 16.55B
-1.13%-4.54%+32.10%+126.95% 16.14B
-7.10%-2.81%-8.80%-34.35% 12.77B
+0.38%+3.70%+2.29%+10.04% 13.71B
Average +0.21%+6.06%+61.03%+107.92% 28.32B
Weighted average by Cap. +0.54%+7.02%+80.33%+135.06%

Financials

2024 2025
Net sales 326K 283K 263K 243K 457K 31.12M 465K 3.11M 1.22M 15.46M 1.22M 1.2M 51.98M 1.34M 1.16M 1.08M 994K 1.87M 128M 1.91M 12.76M 5M 63.35M 5.02M 4.91M 213M
Net income -20.89M -18.14M -16.85M -15.54M -29.27M -1.99B -29.8M -199M -78.1M -990M -78.44M -76.72M -3.33B -22.58M -19.62M -18.22M -16.8M -31.64M -2.16B -32.22M -216M -84.44M -1.07B -84.81M -82.95M -3.6B
Net Debt -373K -324K -301K -277K -523K -35.61M -532K -3.56M -1.39M -17.69M -1.4M -1.37M -59.48M 13.44M 11.67M 10.84M 10M 18.83M 1.28B 19.17M 128M 50.24M 637M 50.46M 49.36M 2.14B
Logo Pluristem Therapeutics
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-